SCHEMBL2966440

SCHEMBL2966440

COc1cc(C2CC(=O)c3ccc(O)cc3O2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 1.00
CYP19A1 P11511 12/20 0.81
POLB P06746 1/20 0.71
CYP1A1 P04798 1/20 0.71
CYP1A2 P05177 1/20 0.71
CYP1B1 Q16678 1/20 0.71
TUBB4A P04350 1/20 0.68
TUBB P07437 1/20 0.68
YES1 P07947 1/20 0.68
TUBA3C P0DPH7 1/20 0.68
TUBA1B P68363 1/20 0.68
TUBA4A P68366 1/20 0.68
TUBB4B P68371 1/20 0.68
TUBB3 Q13509 1/20 0.68
TUBB2A Q13885 1/20 0.68
TUBB8 Q3ZCM7 1/20 0.68
TUBA3E Q6PEY2 1/20 0.68
TUBA1A Q71U36 1/20 0.68
ESR2 Q92731 1/20 0.68
TUBA1C Q9BQE3 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31028359 1.00 PTPN1 (1.00) PTPN1CYP19A1POLBCYP1A1CYP1A2
SCHEMBL29684675 1.00 PTPN1 (1.00) PTPN1CYP19A1POLBCYP1A1CYP1A2
SCHEMBL15756384 0.92 PTPN1 (0.84) PTPN1CYP19A1POLBTUBB4ATUBB
SCHEMBL31028368 0.91 PTPN1 (0.83) PTPN1CYP19A1CYP1A1CYP1A2CYP1B1
SCHEMBL2968419 0.91 PTPN1 (0.83) PTPN1CYP19A1CYP1A1CYP1A2CYP1B1
SCHEMBL17362369 0.88 PTPN1 (0.79) PTPN1CYP19A1TUBB4ATUBBYES1
SCHEMBL5084433 0.87 PTPN1 (0.77) PTPN1CYP19A1POLBCYP1A1CYP1A2
SCHEMBL5084437 0.87 PTPN1 (0.77) PTPN1CYP19A1POLBCYP1A1CYP1A2
Liquirtigenin SCHEMBL718387 0.85 CYP19A1 (0.89) PTPN1CYP19A1TUBB4ATUBBYES1
Butin SCHEMBL68554 0.85 CYP19A1 (1.00) PTPN1CYP19A1POLBCYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180216152-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONE GLYCOSIDE DIHYDROCHALCONES SYMRISE AG (DE) 2018-08-02 US claimed
US-20180135029-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS SYMRISE AG (DE) 2018-05-17 US claimed
US-9877946-B2 Method for treating, managing, inhibiting, or preventing obesity Research & Business Foundation Sungkyunkwan University (KR) 2018-01-30 US claimed
EP-2963109-B1 Process for the biotechnological production of flavanonglycoside dihydrochalcones SYMRISE AG (DE) 2017-09-06 EP claimed
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER SITY (KR) 2017-03-30 US claimed
US-9549908-B2 Composition for inducing differentiation into beige and brown adipocytes and method of inducing the same Research & Business Foundation Sungkyunkwan University, Ltd. (KR) 2017-01-24 US claimed
WO-2016050656-A1 METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS SYMRISE AG (DE) 2016-04-07 WO claimed
EP-3002335-A1 Process for the biotechnological production of flavonoids Symrise AG (DE) 2016-04-06 EP claimed
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2015-12-31 US claimed
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2024-01-02 US disclosed
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2024-01-02 US disclosed
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2021-03-25 US disclosed
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES UNIGEN, INC. (US) 2021-03-25 US disclosed
US-10857082-B2 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN, INC. (US) 2020-12-08 US disclosed
US-7767661-B2 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-7767661-B2 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US disclosed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US disclosed
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae UNIGEN PHARMACEUTICALS, INC. (US) 2008-06-05 US disclosed
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes UNIGEN PHARMACEUTICALS, INC. (US) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087126-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 PTPN1 2153/4885CYP19A1 1244/4885POLB 4459/4885
US-20050267047-A1 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO PTPN1 1357/4885CYP19A1 203/4885POLB 928/4885
US-20150374643-A1 COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME FABP4, PLIN1, PRDM7 PTPN1 2153/4885CYP19A1 1244/4885POLB 4459/4885
US-10857082-B2 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO PTPN1 1357/4885CYP19A1 203/4885POLB 928/4885
US-20210085580-A1 DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES TYR, DDT, HAAO PTPN1 1357/4885CYP19A1 203/4885POLB 928/4885
US-20080132581-A1 particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae TYR, MAOA, CYP51A1 PTPN1 3131/4885CYP19A1 221/4885POLB 797/4885
US-11857657-B2 Diarylalkanes as potent inhibitors of binuclear enzymes TYR, DDT, HAAO PTPN1 1357/4885CYP19A1 203/4885POLB 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.